Trebisov

Researchers are evaluating the efficacy, safety, and tolerability of combining elecoglipron and dapagliflozin compared to each drug alone in adults with type 2 diabetes mellitus T2DM who have not achieved adequate control through lifestyle changes or other glucose-lowering medications. This Phase III study aims to better understand how these treatments work together in managing blood sugar levels in this population. Participants are randomly assigned to one of five groups two groups receive elecoglipron at different dose levels combined with dapagliflozin two groups receive elecoglipron at different dose levels combined with a placebo matching dapagliflozin and one group receives dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The treatment period lasts 40 weeks, during which the effects of the drugs on blood sugar and other health measures will be monitored. Throughout the study, participants will have regular assessments of their blood sugar control, body weight, and blood pressure. Researchers will measure changes in Hemoglobin A1c HbA1c, fasting plasma glucose, and self-monitored blood glucose levels. Other outcomes include weight loss and the need for rescue medication. Safety and tolerability will be closely monitored. Participation in the trial lasts for 40 weeks, during which participants will attend scheduled visits for evaluation and medication monitoring.

Researchers are evaluating the safety and effectiveness of UBT251, a medicine not yet available for prescription, in adults with type 2 diabetes. This study compares UBT251 with semaglutide, an already approved treatment, and their respective placebos. The goal is to see how well different doses of UBT251 lower blood sugar over time. Participants will be randomly assigned to receive either UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. All treatments are given once weekly by injection under the skin. The study follows participants over several weeks, measuring effects at weeks 16, 28, and 40, focusing on blood sugar control and body weight changes. Throughout the study, participants will have regular assessments including blood tests to measure glycated hemoglobin HbA1c, insulin resistance, beta-cell function, fasting glucose, body measurements, blood pressure, cholesterol levels, and other health markers. Safety is monitored by tracking any adverse events, with total participation lasting up to 40 weeks of treatment plus additional safety follow-up.

Researchers are evaluating the effects of a medicine called BI 1815368 in adults aged 18 and older who have a specific eye condition known as centre-involved diabetic macular edema CI-DME. This condition affects vision, and the study aims to find out if BI 1815368 can improve sight and to determine the best dose. The trial is a phase 2, randomized, double-masked, placebo-controlled study designed to assess efficacy, safety, and tolerability. The study has two parts. In the first part, participants are randomly assigned to one of two groups one receiving BI 1815368 tablets and the other receiving placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take the tablets twice daily for about 11 months. Participants stay in the study for about one year, during which they visit the study site 16 times. At these visits, doctors check vision, document any health problems, and take detailed eye pictures. Researchers compare changes over time between the groups to evaluate if the treatment affects vision. The main outcome measured is whether participants gain at least 10 Early Treatment Diabetic Retinopathy Study ETDRS letters in vision at Week 48 compared to baseline.

Researchers are studying the safety and effectiveness of NNC0487-0111 for adults with excess body weight and type 2 diabetes. This Phase 3 clinical trial compares NNC0487-0111 with a placebo to see how well the medicine helps reduce body weight when taken along with diet and exercise changes. Participants have type 2 diabetes for at least six months and meet specific health criteria to join the study. Participants are randomly assigned to receive one of four different doses of NNC0487-0111 or a placebo. Each treatment is given as a weekly injection under the skin using a pre-filled pen injector, targeting areas like the thigh, abdomen, or upper arm. All participants follow a reduced-calorie diet and increase physical activity during the study. The main treatment period lasts 84 weeks, with body weight and other health measures tracked throughout. During the study, participants will have regular assessments including blood tests to check blood sugar levels, cholesterol, and other health markers. Researchers will also monitor waist size, blood pressure, and quality of life related to physical function. Safety is carefully watched by tracking any side effects or adverse events until 88 weeks. Overall, participants are involved in frequent visits and health evaluations to measure treatment impact and safety over nearly two years.

Researchers are conducting a phase 3 randomized, double-masked clinical trial to compare the effects of two treatments, EYP-1901 and Aflibercept, for patients with diabetic macular edema DME. This study aims to evaluate which treatment better improves visual acuity in people affected by this condition. EyePoint Pharmaceuticals, Inc. is leading this study to assess these injectable drugs impact on vision. Participants will receive either EYP-1901 or Aflibercept through intravitreal injections directly into the eye. The study uses a parallel assignment design with participants randomized to one of the two treatment groups. The trial is double-masked to ensure unbiased results, and the primary treatment period focuses on 52 to 56 weeks of follow-up after injections. During the study, participants will have their best-corrected visual acuity measured to assess changes in vision. Researchers will also monitor the frequency of injections required over the 56-week period to evaluate treatment burden. Participants will attend regular study visits for these assessments and safety monitoring throughout the trial duration, which ends in October 2028.